Stocks and Investing
Stocks and Investing
Fri, August 18, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Hartaj Singh Maintained (SPRB) at Buy with Decreased Target to $7 on, Aug 18th, 2023
Hartaj Singh of Oppenheimer, Maintained "Spruce Biosciences, Inc." (SPRB) at Buy with Decreased Target from $8 to $7 on, Aug 18th, 2023.
Hartaj has made no other calls on SPRB in the last 4 months.
There are 3 other peers that have a rating on SPRB. Out of the 3 peers that are also analyzing SPRB, 0 agree with Hartaj's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Hartaj
- Jonathan Wolleben of "JMP Securities" Maintained at Buy with Increased Target to $8 on, Wednesday, August 16th, 2023
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $8 on, Tuesday, August 15th, 2023
- Tiago Fauth of "Credit Suisse" Reiterated at Buy and Held Target at $4 on, Tuesday, May 16th, 2023
Contributing Sources